Market Overview

UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook

Related PCRX
Pacira Pharma Reports Changes to EXPAREL Label, Indication Not Affected
New Study Correlates Use Of EXPAREL For Postsurgical Pain Management With Significant Reductions In Opioid Related Adverse Events

Wedbush maintained Pacira Pharmaceuticals (NASDAQ: PCRX) with an Outperform rating and raised the price target from $23.00 to $32.00.

Wedbush said, "As already preannounced, PCRX reported Q4 EXPAREL sales of $7.8MM, ahead of our original $7.0MM estimate. Q4 total revenues were $10.5MM and GAAP EPS loss was ($0.50) versus our ($0.32) and Street's ($0.42) estimates. The company ended Q4 with about $42.6MM in cash and including proceeds from the January convertible debt offering, we estimate current cash of about $123MM. We project runway well into potential profitability, which we model to occur in 2014."

Pacira Pharmaceuticals closed at $25.30 on Wednesday.

Latest Ratings for PCRX

DateFirmActionFromTo
Oct 2014Bank of AmericaDowngradesBuyNeutral
Aug 2014JefferiesMaintainsBuy
Jul 2014BarclaysMaintainsOverweight

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters